PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters

Modern Pathology

Volumn 21, Issue 2, 2008, Pages 131-139

  Catasus, Lluis ^a   Gallardo, Alberto ^a   Cuatrecasas, Miriam ^a   Prat, Jaime ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Endometrial carcinoma; Histological grade; Myometrial invasion; PIK3CA

Indexed keywords

B RAF KINASE; BETA CATENIN; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; CANCER GRADING; CANCER INVASION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOMETRIUM CARCINOMA; EXON; FEMALE; GENE FREQUENCY; GENE LOCATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; MISSENSE MUTATION; ONCOGENE; PIK3CA GENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; ENDOMETRIAL NEOPLASMS; EXONS; FEMALE; HUMANS; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS;

EID: 38649090091     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800992     Document Type: Article

References (45)

1. American Cancer Society. Cancer Facts and Figures 2007. American Cancer Society: Atlanta, GA, 2007.
2. Prat J. Prognostic parameters of endometrial carcinoma. Hum Pathol 2004;35:649-662.
3. Risinger JI, Berchuck A, Kohler MF, et al. Genetic instability of microsatellites in endometrial carcinoma. Cancer Res 1993;53:5100-5153.
4. Caduff RF, Johnston CM, Svoboda-Newman SM, et al. Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. Am J Pathol 1996;148:1671-1678.
5. Catasus L, Machin P, Matias-Guiu X, et al. Microsatellite instability in endometrial carcinomas clinicopathologic correlations in a series of 42 cases. Hum Pathol 1998;29:1160-1164.
6. Tashiro H, Blazes MS, Wu R, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997;57:3935-3940.
7. Kong D, Suzuki A, Zou TT, et al. PTEN is frequently mutated in primary endometrial carcinomas. Nat Genet 1997;17:143-144.
8. Bussaglia E, del Rio E, Matias-Guiu X, et al. PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic analysis of 38 cases. Hum Pathol 2000;31:312-317.
9. Enomoto T, Inoue M, Perantoni AO, et al. K-Ras activation in premalignant and malignant epithelial lesions of the human uterus. Cancer Res 1991;51:5308-5314.
10. Caduff RF, Johnston CM, Frank TS. Mutations of the c-Ki-Ras oncogene in carcinoma of the endometrium. Am J Pathol 1995;146:182-188.
11. Lagarda H, Catasus L, Arguelles R, et al. K-ras mutations in endometrial carcinomas with microsatellite instability. J Pathol 2001;193:193-199.
12. Fukuchi T, Sakamoto M, Tsuda H, et al. Beta-catenin mutations in carcinoma of the uterine endometrium. Cancer Res 1998;58:3526-3528.
13. Machin P, Catasus L, Pons C, et al. CTNNB1 mutations and beta-catenin expression in endometrial carcinomas. Hum Pathol 2002;33:206-212.
14. Maxwell GL, Risinger JI, Alvarez AA, et al. Favorable survival associated with microsatellite instability in endometrioid endometrial cancers. Obstet Gynecol 2001;97:417-422.
15. Hirasawa A, Aoki D, Inoue J, et al. Unfavorable prognostic factors associated with high frequency of microsatellite instability and comparative genomic hybridization analysis in endometrial cancer. Clin Cancer Res 2003;9:5675-5682.
16. An HJ, Kim KI, Kim JY, et al. Microsatellite instability in endometrioid type endometrial adenocarcinoma is associated with poor prognostic indicators. Am J Surg Pathol 2007;31:846-853.
17. Risinger JI, Hayes K, Maxwell GL, et al. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res 1998;4:3005-3010.
18. Minaguchi T, Yoshikawa H, Oda K, et al. PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas. Clin Cancer Res 2001;7:2636-2642.
19. Salvesen HB, MacDonald N, Ryan A, et al. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer 2001;91:22-26.
20. Saegusa M, Hashimura M, Yoshida T, et al. Beta-catenin mutations and aberrant nuclear expression during endometrial tumorigenesis. Br J Cancer 2001;84:209-217.
21. Brachtel E, Sanchez C, Moreno G, et al. Distinct molecular alterations in complex endometrial hyperplasia (CEH) with and without immature squamous metaplasia (squamous morules). Am J Surg Pathol 2005;29:1322-1329.
22. Campbell IG, Russell SE, Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004;64:7678-7681.
23. Lee JW, Soung YH, Kim SY, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005;24:1477-1480.
24. Samuels Y, Velculescu VE. Oncogenic of PIK3CA in human cancers. Cell Cycle 2004;3:1221-1224.
25. Oda K, Stokoe D, Taketani Y, et al. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 2005;65:10669-10673.
26. Stambolic V, Suzuki A, de la Pompa JL, et al. Negative regulation of PKB/AKT dependent cell survival by the tumor suppressor PTEN. Cell 1998;95:29-39.
27. Velasco A, Bussaglia E, Pallares J, et al. PIK3CA gene mutations in endometrial carcinoma. Correlation with PTEN and K-Ras alterations. Hum Pathol 2006;37:1465-1472.
28. Hayes MP, Wang H, Espinal-Witter R, et al. PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res 2006;12:5932-5935.
29. Samuels Y, Diaz Jr LA, Schmidt-Kittler O, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005;7:561-573.
30. Silverberg SG, Kurman RJ, Nogales F, et al. Tumours of the uterine corpus. In: Tavassoli FA, Devilee P (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press: Lyon, 2003, pp 217-257.
31. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
32. Feng YZ, Shiozawa T, Miyamoto T, et al. BRAF mutation in endometrial carcinoma and hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein expression. Clin Cancer Res 2005;11:6133-6138.
33. Müller C, Miller CW, Hofmannn W-K, et al. Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene. Leuk Res 2007;31:27-32.
34. Bocker T, Diermann J, Friedl W, et al. Microsatellite instability analysis: a multicenter study for reliability and quality control. Cancer Res 1997;57:4739-4743.
35. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-5257.
36. Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol 2006;18:77-82.
37. Buttitta F, Felicioni L, Barassi F, et al. PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. J Pathol 2006;208:350-355.
38. Saal LH, Holm K, Maurer M, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005;65:2554-2559.
39. Gymnopoulos M, Elsliger M-A, Vogt PK. Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci 2007;104:5569-5574.
40. Bader AG, Kang S, Zhao L, et al. Oncogenic PI3K deregulates transcription and translation. Nat Rev 2005;5:921-929.
41. Frattini M, Signoroni S, Pilotti S, et al. Phosphatase protein homologue to tensin expression and phosphatidylinositol-3 phosphate kinase mutations in colorectal cancer. Cancer Res 2005;65:11227.
42. Palacios J, Catasus L, Moreno-Bueno G, et al. Beta- and gamma-catenin expression in endometrial carcinoma. Relationship with clinicopathological features and microsatellite instability. Virchows Arch 2001;438:464-469.
43. Mutch DG, Powell MA, Mallon MA, et al. RAS/RAF mutation and defective DNA mismatch repair in endometrial cancers. Am J Obstet Gynecol 2004;190:935-942.
44. Salvesen HB, Kumar R, Stefansson I, et al. Low frequency of BRAF and CDKN2A mutations in endometrial cancer. Int J Cancer 2005;115:930-934.
45. Pappa KI, Choleza M, Markaki S, et al. Consistent absence of BRAF mutations in cervical and endometrial cancer despite K-Ras mutation status. Gynecol Oncol 2006;100:596-600.